Skin Substitutes Grafts/Cellular and Tissue-Based Products (Injections and/or Applications) – Medicare Advantage Medical Policy | UHC Coverage Update

TL;DR: UnitedHealthcare modified its skin substitutes grafts and cellular and tissue-based products (CTP) coverage policy, effective February 2, 2026. Here's what billing teams need to do.

UnitedHealthcare updated its coverage policy for skin substitute grafts and cellular and tissue-based products (CTP), including amniotic and placental derived product injections and applications for musculoskeletal indications. This policy now covers 302 HCPCS codes—including A2001 through A2039 and Q4100 through Q4249—and governs coverage across both wound and non-wound indications. The real issue is that compliance depends on which state your patient is in, and the LCD/LCA patchwork makes this one of the more operationally complex coverage policies your billing team will manage in 2026.

Quick-Reference Table

UnitedHealthcare Skin Substitute CTP Coverage Criteria and Medical Necessity Requirements 2026

The UnitedHealthcare skin substitutes and CTP coverage policy splits into two distinct tracks. Which track applies depends on the indication—wound care or non-wound musculoskeletal—and whether your state has an active Local Coverage Determination (LCD) or Local Coverage Article (LCA).

For skin substitute grafts and CTPs used in wound care, UnitedHealthcare defers to Medicare LCDs and LCAs. No National Coverage Determination (NCD) exists for these products. Where an LCD or LCA is in place, compliance with that policy is required. There is no workaround.

For amniotic and placental derived product injections and applications for musculoskeletal indications (non-wound), the same framework applies. Medicare has no NCD. LCDs and LCAs govern coverage where they exist. If you're billing Q4139 (AmnioMatrix or BioDMatrix, injectable), Q4145 (EpiFix, injectable), or Q4155 (Neox Flo or Clarix Flo), you need the applicable LCD in hand before you submit.

For states or territories with no LCD or LCA, UnitedHealthcare directs you to its own commercial medical policy titled Skin and Soft Tissue Substitutes. This matters if you serve patients in lower-population states or U.S. territories where MAC coverage hasn't been established.

Medical necessity under this policy is not self-evident from the HCPCS code alone. The product, the indication, the wound type, and the state-specific LCD all interact. A claim for A2001 (InnovaMatrix AC) that's clean in one state may deny in another. Your billing team needs a state-by-state compliance map before submitting any of these codes.

Prior authorization requirements vary by plan and state. UnitedHealthcare commercial and Medicare Advantage plans may apply different prior auth rules. If you're billing under a Medicare Advantage contract, confirm whether the plan's CTP prior authorization requirements mirror Medicare fee-for-service or add additional steps. Don't assume they match.

Reimbursement for CTPs and skin substitutes has been under scrutiny across payers for the past two years. This policy update signals UnitedHealthcare is tightening the compliance framework—not loosening coverage. That's the pattern worth watching.

UnitedHealthcare Skin Substitute CTP Exclusions and Non-Covered Indications

The policy draws a clean line between wound and non-wound indications. Coverage for non-wound musculoskeletal use of amniotic and placental derived products is not governed by open commercial medical necessity standards—it flows through the LCD/LCA framework. If no LCD exists and the UnitedHealthcare commercial policy doesn't support the indication, the claim will not be covered.

For breast reconstruction, coverage is handled under a separate UnitedHealthcare policy. If your team bills skin or soft tissue substitutes alongside breast reconstructive procedures, the skin substitutes CTP policy does not apply. Billing those codes under this policy is a path to claim denial.

Q4100 (Skin substitute, not otherwise specified) was deleted effective January 1, 2026. If your charge capture still includes Q4100, pull it now. Any claim submitted with Q4100 after that date will reject. The replacement billing logic depends on which specific product was used—you'll need to map to the correct product-specific code.

Coverage Indications at a Glance

UnitedHealthcare Skin Substitute Billing Guidelines and Action Items 2026

These are the steps your billing team needs to complete before submitting any skin substitute or CTP claim under this updated policy.

CPT, HCPCS, and ICD-10 Codes for Skin Substitute Grafts/CTPs Under UHC Policy

The policy covers 302 HCPCS codes. Below is the complete list from the policy data. Note that Q4100 is included for reference but was deleted effective January 1, 2026 and is no longer billable.

Covered HCPCS Codes (When LCD/LCA or Commercial Policy Criteria Are Met)

The full policy covers 302 HCPCS codes total. The codes listed above represent the complete set provided in the policy data. For the full code list, access the policy directly at app.payerpolicy.org.

Deleted / Non-Billable Codes